Display options
Cite
Sandler KA, Veruttipong D, Agopian VG, et al. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Adv Radiat Oncol. 2016;1(4):237-243doi: 10.1016/j.adro.2016.10.008.
Sandler, K. A., Veruttipong, D., Agopian, V. G., Finn, R. S., Hong, J. C., Kaldas, F. M., Sadeghi, S., Busuttil, R. W., & Lee, P. (2016). Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Advances in radiation oncology, 1(4), 237-243. https://doi.org/10.1016/j.adro.2016.10.008
Sandler, Kiri A, et al. "Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma." Advances in radiation oncology vol. 1,4 (2016): 237-243. doi: https://doi.org/10.1016/j.adro.2016.10.008
Sandler KA, Veruttipong D, Agopian VG, Finn RS, Hong JC, Kaldas FM, Sadeghi S, Busuttil RW, Lee P. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Adv Radiat Oncol. 2016 Oct 29;1(4):237-243. doi: 10.1016/j.adro.2016.10.008. eCollection 2016. PMID: 28740893; PMCID: PMC5514222.
Copy Download .nbib Format: NLM
Share it on

Adv Radiat Oncol. 2016 Oct 29;1(4):237-243. doi: 10.1016/j.adro.2016.10.008. eCollection 2016.

Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma.

Advances in radiation oncology

Kiri A Sandler, Darlene Veruttipong, Vatche G Agopian, Richard S Finn, Johnny C Hong, Fady M Kaldas, Saeed Sadeghi, Ronald W Busuttil, Percy Lee

Affiliations

  1. Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.
  2. Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California.
  3. Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.

PMID: 28740893 PMCID: PMC5514222 DOI: 10.1016/j.adro.2016.10.008

Abstract

OBJECTIVES: We report single-institution clinical efficacy and safety outcomes for patients with unresectable locally advanced cholangiocarcinoma who were treated with stereotactic body radiation therapy (SBRT) and a subset of patients who received neoadjuvant SBRT and chemotherapy as part of an orthotopic liver transplantation (OLT) protocol.

METHODS AND MATERIALS: From October 2008 to June 2015, 31 consecutive patients with unresectable extrahepatic (n = 25) or intrahepatic (n = 6) cholangiocarcinoma were treated with SBRT and retrospectively analyzed. Four patients underwent liver transplantation, and 1 underwent resection. SBRT was delivered in 5 fractions with a median dose of 40 Gy. Toxicity was scored using the Common Terminology Criteria for Adverse Events Version 4.0. Overall survival (OS), time to progression, and local control were estimated using the Kaplan-Meier method.

RESULTS: The median follow-up time was 11.5 months. The 1- and 2-year OS rates were 59% and 33%, respectively, with a median survival of 15.7 months. The 1- and 2-year freedom from progression was 67% and 34%, respectively. Median time to progression was 16.8 months. Nine patients had local failure. The actuarial 1- and 2-year local control rates were 78% and 47%, respectively. Among patients who also had OLT, the median OS was 31.3 months. Twenty-four patients (77%) experienced some form of acute grade 1-2 toxicity, most commonly fatigue or pain. Five patients (16%) experienced grade ≥3 toxicity.

CONCLUSIONS: SBRT is a promising option for patients with unresectable or recurrent cholangiocarcinoma either as a component of neoadjuvant therapy prior to OLT or as part of definitive therapy for patients who are unresectable and not eligible for transplantation.

References

  1. Cancer. 2015 Apr 1;121(7):1128-37 - PubMed
  2. Pract Radiat Oncol. 2015 May-Jun;5(3):e183-91 - PubMed
  3. Ann Surg. 2007 May;245(5):755-62 - PubMed
  4. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):969-74 - PubMed
  5. Gastroenterology. 2012 Jul;143(1):88-98.e3; quiz e14 - PubMed
  6. Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1420-6 - PubMed
  7. Mayo Clin Proc. 1995 May;70(5):425-9 - PubMed
  8. Semin Liver Dis. 1994 May;14(2):109-14 - PubMed
  9. Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):772-9 - PubMed
  10. Radiat Oncol. 2012 May 03;7:67 - PubMed
  11. Liver Transpl. 2014 Jan;20(1):81-8 - PubMed
  12. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):483-8 - PubMed
  13. Radiat Oncol. 2012 Oct 10;7:166 - PubMed
  14. J Clin Oncol. 2016 Jan 20;34(3):219-26 - PubMed
  15. Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1191-8 - PubMed
  16. Arch Surg. 2011 Jun;146(6):683-9 - PubMed
  17. Radiat Oncol J. 2014 Sep;32(3):163-9 - PubMed
  18. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1371-8 - PubMed
  19. Radiother Oncol. 2010 Jan;94(1):47-52 - PubMed
  20. Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1006-11 - PubMed
  21. Clin Oncol (R Coll Radiol). 2014 Sep;26(9):569-80 - PubMed
  22. J Natl Cancer Inst. 2006 Jun 21;98(12):873-5 - PubMed
  23. Cancer. 2012 Nov 1;118(21):5424-31 - PubMed
  24. Am J Surg. 1991 Apr;161(4):454-8 - PubMed
  25. Radiother Oncol. 2011 May;99(2):120-3 - PubMed

Publication Types